NUCB2 and gastric cancer: Consistently, in the present study, the serum concentrations of NUCB2/nesfatin‐1 were also significantly higher in patients with GC, indicating that blood NUCB2/nesfatin‐1 level may serve as a novel biomarker for the diagnosis of GC.